X-ray crystallography of catechol O-methyltransferase: perspectives for target-based drug development.
Vidgren
J
J
Orion Pharma, Espoo, Finland.
D000818:Animals; D001812:Blood-Brain Barrier; D002394:Catechol O-Methyltransferase / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D002396:Catechols / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D018360:Crystallography, X-Ray / Q000379:methods; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy; D017510:Protein Folding; D017433:Protein Structure, Secondary
D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; C071192:entacapone; D002394:Catechol O-Methyltransferase